Mesoblast (NASDAQ:MESO) had its price objective upped by Maxim Group from $16.00 to $22.00 in a research note published on Friday morning, The Fly reports. Want to see which stocks are moving? MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Data may be intentionally delayed pursuant to supplier requirements.
Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.Get daily stock ideas top-performing Wall Street analysts. Average Target Price: 21.68 Number of Ratings: 7 Current Quarters Estimate:-0.04 FY Report Date: 6 / 2021 Current Year's Estimate:-0.07 Last Quarter's Earnings:-0.31 ET by Tomi Kilgore Mesoblast stock price target raised to … Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines.
Mesoblast had a negative net margin of 197.65% and a negative return on equity of 13.59%. Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Please log in to your account or sign up in order to add this asset to your watchlist. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. They currently have a buy rating on the stock. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom.
Export data to Excel for your own analysis. © American Consumer News, LLC dba MarketBeat® 2010-2020. The business had revenue of $12.20 million during the quarter, compared to the consensus estimate of $9.38 million.
Mesoblast Ltd. Stock Price Forecast, MESO stock price prediction. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Copyright 2020 FactSet Research Systems Inc. All rights reserved. Jefferies Group LLC acquired a new position in shares of Mesoblast in the second quarter worth about $1,025,000. Sit Investment Associates Inc. acquired a new position in shares of Mesoblast in the second quarter worth about $413,000. The lighter blue line represents the stock's consensus price target. What price target have analysts set for MESO? Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation … The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . Goldman Sachs Group Inc. acquired a new position in shares of Mesoblast in the second quarter worth about $2,324,000. All rights reserved. Several other equities research analysts also recently commented on the stock… Get the latest Mesoblast Limited MESO detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. The Daily Biotech Pulse: Poseida's Phase 1 Study Placed On Clinical Hold, Orphan Drug Designation For Krystal Biotech, Tiziana's Patent Award Shanthi Rexaline Tue, 18 Aug 2020 08:19:43 …
Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The Mesoblast Limited (MESO) shares are trading at lower $11.33 and the avg recommendation for the stock is Strong Buy. On average, they anticipate Mesoblast's share price to reach $15.89 in the next year. Mesoblast Limited - MESO - Stock Price Today - Zacks MESO is up today. The chart below shows how a company's share price and consensus price target have changed over time. Get short term trading ideas from the MarketBeat Idea Engine. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Finally, Wilbanks Smith & Thomas Asset Management LLC raised its position in shares of Mesoblast by 111.8% in the first quarter. Price target in 14 days: 24.510 USD. MESO has a greater percentage of analysts bullish on the stock than 78.67% of all US stocks. Based on analysts offering 12 month price targets for MESO in the last 3 months. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy." Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. According to 6 Wall Street analysts that have issued a 1 year MESO price target, the average MESO price target is $18.92, with the highest MESO stock price forecast at $23.00 and the lowest MESO stock price forecast at $5.50. Just enter your email address below.Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! Equities analysts forecast that Mesoblast will post -0.58 EPS for the current year.
See what's happening in the market right now with MarketBeat's real-time news feed. Learn about financial terms, types of investments, trading strategies and more.MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis.
The company reported ($0.14) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.14).
Several other equities research analysts also recently commented on the stock. The dark blue line represents the company's actual price. On average, Wall Street analysts predict that Mesoblast Ltd's share price could reach $18.92 by Aug 27, 2021. 7 equities research analysts have issued 1 year target prices for Mesoblast's stock. Learn everything you need to know about successful options trading with this three-part video course.Looking for new stock ideas? Zacks Investment Research upgraded shares of Mesoblast (NASDAQ:MESO) from a hold rating to a buy rating in a report released on Wednesday, Zacks.com reports.